Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.

[1]  P. Franchimont,et al.  Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. , 1983, Contraception.

[2]  A. Vermeulen,et al.  Metabolic effects of the triphasic oral contraceptive Trigynon. , 1982, Contraception.

[3]  M. Raj,et al.  Normalization of Testosterone Levels Using a Low Estrogen-Containing Oral Contraceptive in Women with Polycystic Ovary Syndrome , 1982, Obstetrics and gynecology.

[4]  R. Wild,et al.  Adrenal function in hirsutism. II. Effect of an oral contraceptive. , 1982, The Journal of clinical endocrinology and metabolism.

[5]  W. Spellacy.  Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. , 1982, American journal of obstetrics and gynecology.

[6]  M. Briggs.  Randomized Prospective Studies on Metabolic Effects of Oral Contraceptives , 1982, Acta obstetricia et gynecologica Scandinavica. Supplement.

[7]  P. Wahl,et al.  Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. , 1981, The Journal of clinical endocrinology and metabolism.

[8]  B. Cohen,et al.  Further studies on pituitary and ovarian function in women receiving hormonal contraception. , 1981, Contraception.

[9]  L. Wallentin,et al.  Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. , 1981, Fertility and sterility.

[10]  P. Kalra,et al.  Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive. , 1980, American journal of obstetrics and gynecology.

[11]  J. Duvivier,et al.  Chromatographie des stéroïdes gonadiques sur Sephadex LH-20 , 1976 .

[12]  K. Aktories,et al.  Dose-dependent inhibition by oral contraceptives of the pituitary to release LH and FSH in response to stimulation with LH-RH+. , 1976, Contraception.

[13]  K. Aktories,et al.  [The effect of different types of oral contraceptives upon ovarian function (author's transl)]. , 1976, Geburtshilfe und Frauenheilkunde.

[14]  W. Wiser,et al.  The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women. , 1976, American journal of obstetrics and gynecology.

[15]  E. Johansson.  Plasma Levels of Progesterone and Oestrogens in Women Treated with an Oral Contraceptive of Low Oestrogen Content (Ovostat 1375) , 1975, Acta obstetricia et gynecologica Scandinavica.

[16]  H. Meiers,et al.  Wirkungen von Antikonzeptiva auf Alopecia androgenetica, Seborrhoea oleosa, Akne vulgaris und Hirsutismus , 1974 .

[17]  A. Vermeulen,et al.  The apparent free testosterone concentration, an index of androgenicity. , 1971, The Journal of clinical endocrinology and metabolism.

[18]  R. Greenblatt,et al.  The Development of a New Triphasic Oral Contraceptive , 1984, Springer Netherlands.

[19]  J. Colau,et al.  [Residual ovarian function after minidoses of estroprogestative agents]. , 1983, Journal de gynecologie, obstetrique et biologie de la reproduction.

[20]  A. Haspels,et al.  Benefits and Risks of Hormonal Contraception , 1982, Springer Netherlands.

[21]  P. Keller.  Hirsutism and Virilism , 1981 .

[22]  K. Aktories.  Die Beeinflussung des Ovarialzyklus durch verschiedene Typen hormonaler Kontrazeptiva , 1977 .

[23]  P. Franchimont,et al.  Homologous radioimmunoassay for human prolactin. , 1976, International journal of nuclear medicine and biology.

[24]  J. Spona,et al.  Inhibition of ovulation by means of a combined preparation with reduced amounts of active substance , 1974 .